- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II single-arm study of pembrolizumab plus lenvatinib in previously treated classic Kaposi sarcoma (CKS)
This study is looking at a new combination treatment for a type of cancer called Kaposi sarcoma that has come back or not responded to previous treatments. It uses two drugs, pembrolizumab and lenvatinib, to see how well they work together.
For: Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
This study is looking at new ways to treat advanced small cell lung cancer for the first time. It combines Pembrolizumab with other medications to see how well they work together and if they are safe.
For: First-line treatment of participants with extensive-stage small cell lung cancerPoland · Hungary · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizuma Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
This study is looking at new treatments for melanoma, a type of skin cancer, that has not responded to previous therapies. Researchers want to see how safe these new treatments are, especially when given with or without a common cancer drug called pembrolizumab (Keytruda).
For: PD-1 refractory melanomaSpain · France · Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
This study looks at new treatments for head and neck cancer that has come back or spread after previous therapies. It compares a new drug, Lenvatinib, alone or with Pembrolizumab, against standard chemotherapy. We want to see if these new approaches help people live longer and improve their health.
For: Recurrent or metastatic squamous cell carcinoma of the head and neckNorway · Denmark · Portugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
This study is looking at a medicine called lenvatinib for children and young people (aged 2-21) with certain types of cancer that haven't responded to other treatments. It wants to see if the medicine can shrink tumours and if it's safe to use.
For: Between ages 2 and 21 and have High Grade Glioma (HGG) · Rhabdomyosarcoma (RMS) · Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET)Spain · Italy · France - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
For: Solid Tumors · Hematologic MalignanciesUnited States · Argentina · Australia - Active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
For: Renal Cell CarcinomaUnited States · Australia · Austria - RecruitingPHASE2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
This study looks at new ways to treat liver cancer before and after surgery. We're testing two drugs, pembrolizumab and lenvatinib, alone or together, to see if they can help stop the cancer from coming back after removal. It’s for people with liver cancer that can be surgically removed.
For: Hepatocellular CarcinomaUnited Kingdom - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
This study is testing a new drug, Farletuzumab Ecteribulin, for certain advanced cancers like ovarian, endometrial, and some breast and lung cancers. Researchers want to see if it's safe, how well it works, and find the best dose.
For: Solid TumorUnited States · France · Japan - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
For: Carcinoma, Renal CellUnited States · Australia · Brazil - Active not recruitingPHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
This study looks at new drug combinations for advanced kidney cancer that has not responded to previous treatments. It aims to see how safe and effective these new combinations are.
For: Carcinoma, Renal CellUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
This study is testing two new drugs, nivolumab and ipilimumab, together for advanced liver cancer (hepatocellular carcinoma). It compares this combination to standard treatments (sorafenib or lenvatinib) to see if it helps people live longer. Participants haven't had prior treatment.
For: Hepatocellular CarcinomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
This study is looking at new ways to treat advanced prostate cancer that has spread and medicines like hormone therapy no longer work. Researchers are testing the drug pembrolizumab, sometimes with other treatments, to see if it's safe and effective, aiming to find better options for patients.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Australia · Canada - RecruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
For: Unresectable Hepatocellular CarcinomaAustria · Belgium · Brazil - Active not recruitingPHASE1, PHASE2
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
This study is looking at new combinations of medicines for kidney cancer (renal cell carcinoma) that has spread or come back. We want to see how safe and effective these new treatments are. It's an early-stage study to find the best way to use these combinations.
For: Carcinoma, Renal CellUnited States · Australia · Canada - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Comparative Bioavailability of Lenvatinib 10 mg Capsules: A Two-Part, Single-Dose, Open-Label, Randomized, Six-Sequence, Three-Treatment, Three-Period, Crossover Pilot Study in Healthy Subjects Under Fasting and Fed Conditions.
This study looks at how a cancer drug called Lenvatinib is absorbed by the body. It helps us understand if different versions of the drug work the same way, and if food affects this absorption. It's for adults, and you don't need to have cancer to take part.
For: Progressive · locally advanced or metastatic · differentiated (papillary/follicular/Hurthle cell) thyroid carcinomaPortugal - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (LEAP-008)
This study looks at new treatments for advanced lung cancer that has already been treated. It compares a combination of two drugs (pembrolizumab and lenvatinib) to another drug (docetaxel) to see which is more effective and safer.
For: NSCLC with squamous or nonsquamous histologyFrance · Italy · Greece - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
This study is looking at new ways to treat advanced oesophageal cancer. We're testing a combination of new drugs and chemotherapy to see if it works better than standard treatments, with a focus on safety and how long people live while on the treatment.
For: Esophageal CarcinomaSpain · Hungary · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination with Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
This study is looking at new treatments for advanced liver cancer in people who haven't had treatment before. Researchers want to see how safe the new treatment is and if it can help slow down or shrink the cancer. It combines a new medicine called MK-1308A with an existing drug, Lenvatinib.
For: Hepatocellular carcinomaSpain · Italy · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
This study is looking at a new combination of medicines (Lenvatinib and Pembrolizumab) plus TACE for people with liver cancer that hasn't spread. We want to see if this combination works better than TACE alone to stop the cancer from growing and help people live longer.
For: Incurable/Non-metastatic Hepatocellular CarcinomaGermany · Portugal · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
This study is looking at a new combination of two medicines, Lenvatinib and KEYTRUDA, for adults with a type of kidney cancer called non-clear cell renal cell carcinoma (nccRCC). It’s in an early stage of testing to see how well patients respond to the treatment.
For: Non-clear Cell Renal Cell CarcinomaItaly · Spain · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
This study is looking at new treatments for advanced or returning womb cancer. It compares a combination of two anti-cancer drugs (pembrolizumab and lenvatinib) with standard chemotherapy. The aim is to see which treatment works best to stop the cancer from growing and to help people live longer.
For: Participants with advanced or recurrent endometrial carcinomaIreland · Austria · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)
This study is looking at a new combination of medicines for some types of cancer, called MK-4280A and pembrolizumab. It wants to see how well these medicines shrink tumours and if they help people feel better. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
For: Neoplasm malignantFrance · Italy · Netherlands - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-label, Rolling-arm, Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02A
This study is testing new combinations of medicines for advanced melanoma that hasn't responded to previous treatment. Researchers want to see if these new treatments are safe and if they can shrink tumours. It's for adults aged 18 and over.
For: PD-1 refractory melanomaFrance · Italy - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)
This study looks at new drug combinations for advanced stomach or food pipe cancer. It compares a new mix of drugs (Lenvatinib, Pembrolizumab, and chemotherapy) against the usual treatment to see which works best and is safest for patients.
For: Advanced/Metastatic Gastroesophageal AdenocarcinomaSpain · Belgium · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI”.
This study is testing a new combination of two medicines, Keytruda and Lenvatinib, for people with a type of rare cancer called thymic carcinoma or B3-thymoma that has spread. Doctors want to see if this treatment stops the cancer from growing for at least five months and if it's safe.
For: Metastatic Thymic Carcinoma & B3-thymoma.Spain · France · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
This study, called KEYMAKER-U02, is for adults with advanced melanoma, a type of skin cancer, that has spread to the brain. It's looking at new ways to treat this cancer, sometimes using a drug called pembrolizumab (Keytruda) alone, or in combination with other medicines like Lenvatinib or MK-1308A.
For: Advanced melanoma with brain metastases · PD-1 refractory or PD-1 naiveHungary · Poland · Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label, Phase 2 Basket Study of MK‑7684A, a Co formation of Vibostolimab (MK‑7684) With Pembrolizumab (MK‑3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (KEYVIBE 005)
This study, called KEYVIBE 005, is testing a new combination of medicines (MK-7684A, which includes vibostolimab and pembrolizumab) for people with advanced solid tumours. Researchers want to see how well this new treatment shrinks tumours and stops them from growing, either alone or with other cancer therapies.
For: Advanced solid tumorsSpain · Italy · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
This study looks at new drug combinations, including KEYTRUDA, for people with advanced lung cancer. Researchers want to see how well these combinations shrink cancer (response rate) and whether they are safe.
For: Stage IV non-small cell lung cancerItaly · Spain · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)
This study looks at a new drug, CS1003, combined with an existing treatment, Lenvatinib, for people with advanced liver cancer that can't be removed by surgery. Researchers want to see if this combination helps people live longer compared to Lenvatinib alone.
For: Unresectable advanced hepatocellular carcinomaPoland · Spain - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study compares two treatments for advanced kidney cancer: a combination of belzutifan and lenvatinib, versus cabozantinib. It's for people whose cancer has grown even after previous treatment, aiming to find which option works better and is safer.
For: Carcinoma, Renal CellUnited States · Argentina · Australia - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - AuthorisedTherapeutic exploratory (Phase II)
A Phase II single arm open label study of Pembrolizumab and Lenvatinib in patients with high risk locally advanced cervix cancer: an EMBRACE high risk study initiative
This study looks at two medicines, Lenvatinib and Keytruda, for women with a type of womb-neck cancer that is advanced or hasn't responded well to usual treatments. It's a Phase II study, meaning researchers are checking if these medicines together are a good option.
For: high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancerNetherlands